Kiora Pharmaceuticals, Inc.

KPRX Healthcare Biotechnology

Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.

2.40 0.01 −0.41%
Market cap
$10.7M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
n/a
Altman Z
−3.16
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.97 6.68 5.99 8.79
Net Debt/EBITDA
7.64 5.55 2.34 24.72
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.31) (0.76) (0.54) (0.30)
Book value per Share
2.73 3.34 3.87 5.30
Free Cash Flow
(1.92) (3.17) (2.26) (1.27)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates